Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Change in Cash: 2010-2025

Historic Change in Cash for Ironwood Pharmaceuticals (IRWD) over the last 15 years, with Sep 2025 value amounting to $47.6 million.

  • Ironwood Pharmaceuticals' Change in Cash rose 374.68% to $47.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $52.2 million, marking a year-over-year increase of 324.49%. This contributed to the annual value of -$3.6 million for FY2024, which is 99.36% up from last year.
  • As of Q3 2025, Ironwood Pharmaceuticals' Change in Cash stood at $47.6 million, which was up 404.27% from -$15.6 million recorded in Q2 2025.
  • In the past 5 years, Ironwood Pharmaceuticals' Change in Cash ranged from a high of $84.1 million in Q1 2023 and a low of -$565.5 million during Q2 2023.
  • Moreover, its 3-year median value for Change in Cash was -$15.6 million (2025), whereas its average is -$47.0 million.
  • Data for Ironwood Pharmaceuticals' Change in Cash shows a peak YoY increase of 414.44% (in 2023) and a maximum YoY decrease of 535.30% (in 2023) over the last 5 years.
  • Ironwood Pharmaceuticals' Change in Cash (Quarterly) stood at $45.9 million in 2021, then skyrocketed by 78.87% to $82.0 million in 2022, then tumbled by 123.54% to -$19.3 million in 2023, then soared by 101.80% to $348,000 in 2024, then skyrocketed by 374.68% to $47.6 million in 2025.
  • Its last three reported values are $47.6 million in Q3 2025, -$15.6 million for Q2 2025, and $19.9 million during Q1 2025.